genzyme makes expensive investment for safety in Framingham
12 May 2012, 11:36 pm
Police say they have issued 277 citations and billed genzyme $75,000 for safety details outside the biotech firm’s Tech Park campus since an employee was hit in a crosswalk in January.

Being Green Makes Work Life at genzyme a Dream
10 May 2012, 1:43 am
By Cheryl Meyerson, Founder, new city, inc. Since Boston is a hub for green technology, I thought it would be...

genzyme Announces Regulatory Approvals of Expanded Waterford, Ireland Manufacturing Plant
3 May 2012, 12:00 am
genzyme, a Sanofi company , announced today that the Food and Drug Administration and the European Medicines Agency have approved a second

Sanofi first quarter profit climbs 13% on genzyme, Lantus
27 April 2012, 1:59 pm
Sanofi CEO Chris Viehbacher led the purchase of Cambridge, Mass.-based genzyme, the largest maker of medicines for rare genetic disorders, one year ago for $20.1 billion.

Sanofi: Strong performance in Q1 2012 including genzyme contribution
27 April 2012, 6:30 am
PARIS, April 27, 2012 /PRNewswire/ --(Logo:  http://photos.prnewswire.com/prnh/20110616/NY20158LOGO  ) Q1 2012 Change on areported basis Change at constantexchange rates Net sales euro 8,511m +9.4% +7.0% ...

Sanofi First-Quarter Net Climbs 13% on genzyme, Lantus
27 April 2012, 12:52 am
Sanofi, France’s largest drugmaker, said first-quarter profit rose 13 percent, helped by the purchase of U.S. biotechnology genzyme Corp. and higher sales of diabetes medicine Lantus.

genzyme touts potential treatments for MS
25 April 2012, 1:12 pm
genzyme Corp. executives say impending fragmentation in the multiple sclerosis market, and genzyme’s deep experience in patient-focused rare disease markets, will allow the subsidiary of french drug maker Sanofi to become a leader in the $12.5 billion multiple sclerosis (MS) market.

genzyme: 2 potential treatments to be leaders MS market
25 April 2012, 11:12 am
genzyme Corp. executives say impending fragmentation in the multiple sclerosis market, and genzyme’s deep experience in patient-focused rare disease markets, will allow the subsidiary of french drug maker Sanofi to become a leader in the $12.5 billion multiple sclerosis (MS) market.

Sanofi's genzyme Says MS Drug Lemtrada Shows More Trial Success
24 April 2012, 3:16 pm
genzyme, the U.S. biotechnology unit of France's Sanofi SA (SNY), Tuesday said latest results from a late-stage clinical study showed its multiple sclerosis drug Lemtrada significantly reduced relapses and any worsening of the condition, and in some cases showed a reversal in disability.

Sanofi Is Looking at New Compounds to Expand MS Business
24 April 2012, 2:13 pm
Sanofi (SAN) , which bought genzyme Corp. last year, is seeking new treatments to expand its multiple sclerosis business, said Michael Panzara, genzyme’s therapeutic area head for multiple sclerosis, immune diseases and neurology.